Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321477
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2006-05-01
Brief Title:
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IIa study to evaluate the efficacy safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence frequency and nocturia associated with overactive bladder in women
Detailed Description:
A Twelve-Week Randomized Double-Blind Placebo-Controlled Parallel Group Forced Titration Proof of Concept Study to Assess the Efficacy Safety and Tolerability as well as the Pharmacokinetic Profile of 60 mg and 120 mg of GW679769 administered once daily vs Placebo in Women with Overactive Bladder
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None